Stocktoria

Decoy Therapeutics Inc. DCOY

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-01-29 · LEI

Decoy Therapeutics Inc. statistics & valuation

Market cap$2.9M
P / B0.5×
Return on capital-214.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-3946.50% -2724.60% -86.30% -238.50% -148.80% -696.30% 2016201720182019202020212022202320242025
Return on equity (%)
-66.60% -65.60% -33.20% -33.00% -304.40% -237.20% -368.80% -212.60% 2016201720182019202020212022202320242025
Shares outstanding
16.8M 17.8M 2.0M 4.5M 23.8M 1.8M 2.3M 492304 96077 531968 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-62.50% -98.40% -25.20% -49.90% -29.50% -31.30% -215.70% -190.40% -184.40% -113.20% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-3226.70% -2184.10% 214.10% -334.20% -197.10% -554.30% 2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
-$0.50 -$7.72 -$14.88 -$30.74 -$69.54 -$129.10 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin————-696.3%-148.8%-238.5%-86.3%-2724.6%-3946.5%
Net margin————-693.8%-140.5%-200.2%-85.6%-2701.7%-3907.6%
FCF margin————-554.3%-197.1%-334.2%214.1%-2184.1%-3226.7%
Return on assets-113.2%-184.4%-190.4%-215.7%-31.3%-29.5%-49.9%-25.2%-98.4%-62.5%
Return on equity-212.6%-368.8%-237.2%-304.4%-33.0%-33.2%-65.6%131.4%1187.2%-66.6%
Current ratio2.131.98—————5.765.9116.06

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.